High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma

Sven H. Loosen, Frank Tacke, Niklas Puthe, Marcel Binneboesel, Georg Wiltberger, Patrick H. Alizai, Jakob N. Kather, Pia Paffenholz, Thomas Ritz, Alexander Koch, Frank Bergmann, Christian Trautwein, Thomas Longerich, Christoph Roderburg, Ulf P. Neumann, Tom Luedde

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)947-955
Number of pages9
JournalCarcinogenesis
Volume40
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • CANCER
  • CELLS
  • UPAR
  • GEMCITABINE
  • SUPPRESSION
  • EXPRESSION
  • MORTALITY
  • DIAGNOSIS
  • GROWTH

Cite this

Loosen, S. H., Tacke, F., Puthe, N., Binneboesel, M., Wiltberger, G., Alizai, P. H., Kather, J. N., Paffenholz, P., Ritz, T., Koch, A., Bergmann, F., Trautwein, C., Longerich, T., Roderburg, C., Neumann, U. P., & Luedde, T. (2019). High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. Carcinogenesis, 40(8), 947-955. https://doi.org/10.1093/carcin/bgz033